Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Fatemeh Saberi Hosnijeh*, Lina van der Straten, Arnon P. Kater, Marinus H. J. van Oers, Ward F. M. Posthuma, Martine E. D. Chamuleau, Mar Bellido, Jeanette K. Doorduijn, Michel van Gelder, Mels Hoogendoorn, Fransien de Boer, G. Doreen te Raa, J. Martijn Kerst, Erik W. A. Marijt, Reinier A. P. Raymakers, Harry R. Koene, Martijn R. Schaafsma, Johan A. Dobber, Sanne H. Tonino, Sabina S. KerstingAnton W. Langerak, Mark-David Levin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Despite recent identification of several prognostic markers, there is still a need for new prognostic parameters able to predict clinical outcome in chronic lymphocytic leukemia (CLL) patients. Here, we aimed to validate the prognostic ability of known (proteomic) markers measured pretreatment and to search for new proteomic markers that might be related to treatment response in CLL. To this end, baseline serum samples of 51 CLL patients treated with chemo-immunotherapy were analyzed for 360 proteomic markers, using Olink technology. Median event-free survival (EFS) was 23 months (range: 1.25–60.9). Patients with high levels of sCD23 (>11.27, p = 0.026), sCD27 (>11.03, p = 0.04), SPINT1 (>1.6, p = 0.001), and LY9 (>8.22, p = 0.0003) had a shorter EFS than those with marker levels below the median. The effect of sCD23 on EFS differed between immunoglobulin heavy chain variable gene-mutated and unmutated patients, with the shortest EFS for unmutated CLL patients with sCD23 levels above the median. Taken together, our results validate the prognostic impact of sCD23 and highlight SPINT1 and LY9 as possible promising markers for treatment response in CLL patients.
Original languageEnglish
Pages (from-to)55-60.e6
JournalExperimental Hematology
Early online date2020
Publication statusPublished - Sept 2020

Cite this